Veru (VERU)

• Market cap: $50.1M
• 1 day: -2.01%
• 5 days: 6.21%
• 1 month: -34.86%
• 3 months: -32.81%
• 6 months: -35.59%
• Year to date: -47.55%
• 1 year: -60.09%
• 5 years: -87.52%
• 10 years: -74.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Employees: 210

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 30

7% less funds holding

Funds holding: 129 [Q1] → 120 (-9) [Q2]

8.77% less ownership

Funds ownership: 32.35% [Q1] → 23.58% (-8.77%) [Q2]

13% less capital invested

Capital invested by funds: $23.2M [Q1] → $20.1M (-$3.1M) [Q2]

15% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 34

51% less call options, than puts

Call options by funds: $202K | Put options by funds: $411K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 485% upside
• Avg. target: $20 485% upside
• High target: $20 485% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Gary Nachman

485% upside $20

Outperform Maintained

13 Aug 2025